Location History:
- Biberach an der Riss, DE (2020)
- Meetenberg, DE (2021)
- Mettenberg, DE (2012 - 2023)
Company Filing History:
Years Active: 2012-2025
Title: Holger Wagner: A Trailblazer in Plasma Kallikrein Inhibitor Patents
Introduction:
Holger Wagner, a brilliant innovator based in Mettenberg, Germany, is a renowned inventor in the field of plasma kallikrein inhibitors. With an impressive portfolio of 29 patents to his name, Wagner has made significant contributions to the development of novel compounds and treatments for various diseases. This article explores Wagner's latest patents, career highlights, and collaborations, highlighting his remarkable achievements in the field.
Latest Patents:
Holger Wagner's latest patents revolve around heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors. The first patent, titled "Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors," discloses the novel compounds of formula (I), along with their pharmaceutically acceptable salts. These compounds show potential in the treatment of diseases influenced by the inhibition of plasma kallikrein.
The second patent, also titled "Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors," focuses on compounds of formula (I) where Y, R, and Ar are defined. Similar to the previous patent, this patent emphasizes the use of these compounds for treating diseases that can be influenced by plasma kallikrein inhibition. Wagner's ingenuity shines through these patents, which contribute to advancements in medical treatments.
Career Highlights:
Holger Wagner's association with Boehringer Ingelheim International GmbH has played a vital role in his success as an inventor. Boehringer Ingelheim International GmbH, one of the leading pharmaceutical companies globally, is known for its dedication to scientific excellence and the development of innovative solutions. Wagner's affiliation with this renowned company highlights his exceptional abilities and expertise in the field. His numerous patents are a testament to his commitment to pushing the boundaries of innovation in healthcare.
Collaborations:
Innovation often thrives through collaboration, and Holger Wagner has benefitted from the expertise and teamwork of his coworkers. Notably, he has collaborated with Matthias Eckhardt and Elke Langkopf, fellow inventors who have also made significant contributions in the field of plasma kallikrein inhibitors. Such collaborations foster a creative environment and facilitate the exchange of ideas, leading to groundbreaking inventions. Wagner's collaborations demonstrate his ability to work effectively within a team, contributing to broader advancements in the scientific community.
Conclusion:
Holger Wagner's remarkable journey as an inventor places him at the forefront of plasma kallikrein inhibitor patents. With an impressive portfolio of 29 patents, including his latest innovations in heteroaromatic carboxamide derivatives, Wagner has made substantial contributions to the medical field. His association with Boehringer Ingelheim International GmbH and collaborations with esteemed colleagues further solidify his position as a trailblazer in the industry. Wagner's dedication to innovating novel treatments for diseases driven by plasma kallikrein inhibition continues to inspire and shape the future of medical advancements.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.